See below for research we presented at ISPOR 2019

PND89: Persistence To Oral And Injectable Multiple Sclerosis Disease-Modifying Therapies

Prior research in Multiple Sclerosis has shown strong persistence to oral Disease-Modifying Therapies (DMT’s) compared with injectables, with medication possession ratios >85%. Given the increasing availability of oral DMT options, this study explores changes in real-world DMT persistence over time, as well as utilization in relapsing-remitting versus progressive disease.  Read more here.

PMU8: A Systematic Approach For Synthetic Replication Of Clinical Trial Cohorts Using Retrospective Real-world And Clinical Trial Data

Replication of clinical trials through retrospective data has potential applications ranging from in silico modeling and synthetic control arm creation to extrapolation of clinical trial findings to real world practice. We outline here a systematic approach leveraging common data standards for data pooling and study replication.  Read more here.


PCN246: A Systematic Approach For Quantifying Heterogeneity Within Clinical Trial Populations

Heterogeneity in clinical trial populations can contribute to variability in observed treatment effect. According to the Cochrane Handbook, sources can be either clinical or methodological diversity. Two proven quantitative approaches to addressing heterogeneity include use of clustering algorithms and of propensity score modeling techniques. We propose here a quantitative, systematic, scalable approach to assessing clinical trial population heterogeneity.  Read more here.

PCN219: Predicting Chemotherapy-associated Thrombocytopenia In Real World Clinical Settings

Chemotherapy-induced thrombocytopenia is a frequent challenge in the management of cancer patients and can limit the ability to maintain effective dosing and treatment duration. In this study, we assess real-world rates of chemotherapy-associated thrombocytopenia, measure the impact on patient dosing, and explore the potential of machine learning methods, using commonly available clinical variables, to predict development of this common, potentially treatment-limiting side effect.  Read more here.

PND90: Real World Replication Of Clinical Trial Findings In Alzheimer’s Disease

While randomized controlled clinical trials are the gold standard for demonstrating efficacy, there is a need to facilitate comparison of trial findings with real world populations. In this study we replicate the study cohort from an Alzheimer’s trial in a real-world data source, leveraging common data modeling and vocabularies.  Read more here.